Joanne F. Chou

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

39h-index8.3kcitations456works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(178), Esophageal Cancer Research and Treatment(148), Lung Cancer Treatments and Mutations(102), Cancer Genomics and Diagnostics(91), Pancreatic and Hepatic Oncology Research(75)

Publications456 total

Supplementary Table S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S8 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S6 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Methods S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S9 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S10 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S6 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S8 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Figure S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
Supplementary Table S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025Open Access
page 1 of 23Next →

Frequent Co-authors

Marinela Capanu(26), Eileen M. O’Reilly(18), Michael F. Berger(12), David P. Kelsen(11), Diane Reidy‐Lagunes(11), Leonard B. Saltz(11), Andrea Cercek(10), William R. Jarnagin(10), Anna M. Varghese(10), Kenneth H. Yu(9), Zsofia K. Stadler(9), Nancy E. Kemeny(9), Ghassan K. Abou‐Alfa(9), Christine A. Iacobuzio–Donahue(8), Maeve A. Lowery(7), Michael I. D’Angelica(7), T. Peter Kingham(7), Ronald P. DeMatteo(7), Peter J. Allen(7), Wungki Park(7)